Nebracin DM 3 gm

Nebracin DM 3 g is an oral powder/granule formulation intended for reconstitution as a syrup or suspension. The product combines an expectorant/antitussive and an antibacterial adjunct in a single preparation (commonly marketed compositions include combinations such as ambroxol or bromhexine with dextromethorphan, or an antibiotic adjunct depending on regional formulations). The “3 g” denotes the total weight of the reconstituted oral preparation or sachet contents; exact active-ingredient composition and concentrations vary by manufacturer and region and should be confirmed on the product label. Nebracin DM 3 g is intended for symptomatic relief in acute respiratory conditions with a productive cough and for short-term use as directed by a prescriber. It is a prescription or pharmacist-dispensed product in many markets and should be used according to product labeling and clinician advice.

Key Features

How Nebracin DM Works

Nebracin DM pairs two complementary actions:

• Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding the 30S ribosomal subunit, thereby halting the growth of susceptible gram-negative and some gram-positive bacteria commonly implicated in ocular infections. This action helps clear bacterial pathogens causing conjunctivitis, blepharitis, or superficial corneal infections.
• Dexamethasone is a potent corticosteroid that suppresses inflammatory pathways (reducing prostaglandin and cytokine production), thereby decreasing redness, swelling, pain, and discomfort associated with inflammatory or post-operative ocular conditions. The anti-inflammatory effect helps reduce tissue damage and symptomatic inflammation, while the antibiotic component controls infection.

Together, these actions allow Nebracin DM ointment to treat infectious eye conditions where inflammation is a significant component and where combined antimicrobial and anti-inflammatory therapy is clinically indicated.

Indications / Uses

Nebracin DM ophthalmic ointment is used in clinical contexts where a combined antibiotic + steroid formulation is appropriate, including but not limited to:

• Bacterial conjunctivitis with significant inflammation.
• Blepharitis or lid infections when bacterial infection and inflammatory signs coexist.
• Adjunctive treatment after ocular surgery or minor ocular trauma, where the clinician judges simultaneous anti-infective and anti-inflammatory therapy useful (under strict ophthalmic supervision).

Important: Because steroids can worsen certain infections (for example, herpetic keratitis or fungal infections), Nebracin DM should only be used when a bacterial cause is confirmed or strongly suspected and under prescriber oversight.

Dosage & How to Use

General guidance — follow your prescriber’s instructions and the product insert. The following reflects common clinical practice but is not a substitute for individual medical advice:

1. Wash hands thoroughly before handling the tube and before/after instillation.
2. Tilt the head back and gently pull down the lower eyelid to form a small pouch.
3. Apply a small strip of ointment (usually a ribbon approximately 0.5–1.0 cm) into the lower conjunctival sac. Avoid touching the tip of the tube to the eye or eyelids.
4. Close the eye gently for a minute and blot any excess that runs onto the cheek. Keep your eyes closed for a short time to allow the ointment to spread.
5. Typical frequency: as prescribed (often 3–4 times daily for active infection), with exact dosing and duration determined by the treating clinician. Do not exceed the recommended duration without review.

Notes: ointment formulations may temporarily blur vision after application; plan activities accordingly. For infants or non-cooperative patients, a clinician or caregiver should demonstrate correct technique.

Expected Benefits

• Rapid reduction in inflammation: dexamethasone helps reduce redness, swelling and discomfort.
• Bacterial clearance: tobramycin targets common ocular bacteria, shortening infection duration and preventing spread.
• Combined therapy convenience: single-product dosing when both antimicrobial and anti-inflammatory actions are needed reduces regimen complexity.

Effect size and time to symptom relief vary by severity and the organism involved; clinical improvement is often noted within days, but full resolution may take longer depending on the diagnosis.

Side Effects

Most side effects are local and reversible on stopping treatment, but some require prompt medical review:

Common / usually reversible

• Temporary blurred vision immediately after application (ointment base).
• Local irritation, burning, stinging, or increased lacrimation.
• Eyelid skin irritation or contact dermatitis in sensitive individuals.

Less common / clinically significant

• Raised intraocular pressure (IOP): corticosteroids can raise IOP in steroid responders; monitoring is recommended for prolonged courses.
• Delayed corneal healing or masking of severe infection: prolonged steroid use can mask signs of worsening infection and, in some cases, worsen certain non-bacterial infections (herpes simplex, fungal). Use only under clinician’s supervision.

If severe eye pain, vision changes, eye swelling, signs of hypersensitivity, or worsening symptoms occur, stop use and seek ophthalmic evaluation immediately.

Interactions & Important Clinical Notes

• Other topical ocular drugs: When multiple topical eye medications are used, separate applications by several minutes to avoid dilution or washout. Consult your eye specialist about the timing and sequence of drops/ointments.
• Contact lenses: Remove soft contact lenses before application and wait at least 15 minutes (or as advised) before reinserting; preservatives in some formulations may irritate lenses.
• Systemic interactions: Systemic absorption from topical ocular ointment is low, but systemic corticosteroid effects are possible with prolonged or high-dose use. Inform your clinician about concurrent systemic steroid use or immunosuppressants.

Pharmacokinetics

Topically applied to the conjunctival sac, both active agents are primarily intended for local ocular action. Systemic absorption is minimal under normal use; however, measurable systemic levels have been reported with prolonged or extensive application. Because dexamethasone is a steroid, prolonged exposure can theoretically produce systemic steroid effects, so clinicians typically use the lowest effective dose for the shortest duration required.

Precautions & Who Should Be Careful

• Do not use if allergic to tobramycin, dexamethasone, or any component of the ointment.
• Avoid use in known or suspected viral (herpetic), fungal, or protozoal ocular infections unless a specialist advises otherwise, as steroids can worsen these conditions.
• Diabetes, glaucoma, or ocular hypertension: steroid use may require monitoring of intraocular pressure.
• Pregnancy & breastfeeding: consult an eye specialist or obstetrician; topical ocular exposure is generally low but discuss risk/benefit.

Storage & Handling

Store at room temperature as indicated on the product label. Protect from excessive heat and direct sunlight. Keep the tube tip clean; do not touch the tip to any surface. Replace cap after use and keep out of reach of children.

Practical Tips & Realistic Expectations

• Expect temporary blurring after ointment use—avoid driving or operating machinery until vision clears.
• Use for the full course prescribed; stopping early can lead to recurrence.
• If symptoms persist beyond the anticipated course or worsen, return to the clinician for re-evaluation and possible culture/sensitivity testing.

Conclusion

Nebracin DM 3 gm ointment is a practical combined antibiotic-steroid ophthalmic preparation (tobramycin 0.3% + dexamethasone 0.1%) intended to treat bacterial ocular infections accompanied by inflammatory signs. When used appropriately and under medical supervision it provides both antimicrobial action and symptomatic anti-inflammatory benefit; however, steroid components require careful clinical judgement to avoid masking or exacerbating non-bacterial infections and to monitor for steroid-related adverse effects.

References

• https://pmc.ncbi.nlm.nih.gov/articles/PMC6380727/
• https://pubmed.ncbi.nlm.nih.gov/39745078/

FAQ’s